Abstract Background Biological therapies (BTs) including infliximab (IFX), adalimumab
(ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment …

Background: Biologics are used to treat moderate-to-severe psoriasis, and persistence to
biologics may reflect clinical effectiveness. Limited information describing how biologics are …

Introduction Our aim was to study drug survival and associated costs of biologic treatment in
a German real-world cohort of biologic-naïve psoriasis patients. Methods We utilized a …

Biologics are efficacious for treating psoriasis vulgaris (PsV) and psoriatic arthritis (PsA), but
sometimes must be terminated or changed for various reasons including ineffectiveness or …

Introduction Biologic treatments for psoriasis are commonly switched. Treatment persistence
represents an important parameter related to long-term therapeutic performance. The …

Importance Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved
significantly throughout the era of biologics. Clinical trials are inadequate to assess the …

Background Long‐term clinical effectiveness of biologics in psoriasis is needed. Objectives
We aimed to assess the long‐term persistence of biologics used to treat psoriasis in a real …

Persistence is an important component of therapeutic success, which depends on a variety
of factors. Persistence measured under optimal conditions during clinical trials does not …

Background Psoriasis is a chronic, immune-mediated, systemic inflammatory disorder
associated with high costs. This study evaluated real-world treatment patterns and …

Psoriasis is a common chronic recurrent inflammatory disease. Plaque psoriasis accounts
for more than 90% of psoriasis patients. Currently, no therapies are curative. Biologics have …